Waylon Steele
Family · Reading, PANPI 1730627944
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Galderma Laboratories, L.p. at 45.1% of the total. 2025 is the largest year on record at $5,820, 3.7 times the $1,572 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $33.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$7K
- Johnson & Johnson$4K
- AbbVie$914
- Arcutis Biotherapeutics, Inc.$594
- Novartis$357
- UCB, Inc.$239
- plus $2K from 24 others
What the payments were for
- Consulting fees$2,26316%
- Speaking & faculty fees$4,35030%
- Food & beverage$7,55752%
- Education$4013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 112 | $6,570 |
| Johnson & Johnson(2 entities) | 87 | $4,149 |
| AbbVie | 90 | $914 |
| Arcutis Biotherapeutics, Inc. | 32 | $594 |
| Novartis | 19 | $357 |
| UCB, Inc. | 15 | $239 |
| VYNE Pharmaceuticals Inc. | 17 | $207 |
| Sanofi | 8 | $201 |
| Sun Pharmaceutical Industries Inc. | 7 | $142 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $130 |
| Regeneron Healthcare Solutions, Inc. | 2 | $128 |
| Lilly USA, LLC | 6 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $96 |
| Incyte Corporation | 5 | $93 |
| LEO Pharma Inc. | 3 | $65 |
| Mayne Pharma Commercial LLC | 3 | $62 |
| Genentech USA, Inc. | 3 | $58 |
| Pfizer | 3 | $57 |
| Dermavant Sciences, Inc. | 3 | $52 |
| Verrica Pharmaceuticals Inc. | 2 | $47 |
| EPI Health, LLC | 3 | $46 |
| Botanix SB Inc | 2 | $44 |
| Journey Medical Corporation | 2 | $38 |
| Boehringer Ingelheim | 2 | $33 |
| Amgen | 2 | $29 |
| Merz North America, Inc. | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $26 |
| Organogenesis Inc. | 1 | $23 |
| Almirall LLC | 1 | $22 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,570 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 12 | $60,166 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 246 | $3,765 |
| Ketoconazole | 115 | $2,819 |
| Fluorouracil | 19 | $1,258 |
| Metronidazole | 18 | $1,232 |
| Triamcinolone Acetonide | 87 | $1,172 |
| Imiquimod | 25 | $711 |
| Clobetasol Propionate | 21 | $500 |
| ValacyclovirValacyclovir Hcl | 20 | $431 |
| Doxycycline Hyclate | 14 | $422 |
| Mupirocin | 43 | $295 |
| Ammonium Lactate | 13 | $224 |
| Finasteride | 15 | $203 |
| Hydrocortisone | 41 | $132 |
| Dutasteride | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $29 | $60,16612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Reading
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.